Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Operating Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Operating Expenses for 3 consecutive years, with $33.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 27.75% to $33.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $155.4 million, a 58.17% decrease, with the full-year FY2024 number at $331.6 million, up 50.05% from a year prior.
  • Operating Expenses was $33.8 million for Q3 2025 at Inhibrx Biosciences, up from $28.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $161.0 million in Q2 2024 to a low of $28.7 million in Q2 2025.
  • A 3-year average of $61.4 million and a median of $46.4 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 289.18% in 2024, then crashed 82.18% in 2025.
  • Inhibrx Biosciences' Operating Expenses stood at $89.9 million in 2023, then plummeted by 44.37% to $50.0 million in 2024, then crashed by 32.41% to $33.8 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Operating Expenses are $33.8 million (Q3 2025), $28.7 million (Q2 2025), and $42.9 million (Q1 2025).